Press Room

UK and Ireland News


20 May, 2021
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer

25 March, 2021
New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer

9 December, 2020
RxPONDER study results demonstrate that the Oncotype DX® Test can now spare chemotherapy use in the majority of women with node-positive early-stage breast cancer

2 October 2020
New real-world evidence further demonstrates the Oncotype DX Breast Recurrence Score® Test’s clinical utility, beyond clinical risk factors, in guiding chemotherapy treatment decisions in patients with early-stage breast cancer

29 May 2020
New data and society guidelines support value of Oncotype DX Breast Recurrence Score® Test in guiding neoadjuvant treatment decisions for newly diagnosed patients

14 May 2020
New Oncotype DX® real-world evidence shows for the first time the practice-changing impact of TAILORx results


2019 Archive

12 December 2019
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer

2 October 2019
New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment

21 June 2019
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test

4 June 2019
Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision

25 March 2019
Evidence from UK hospitals supports the value of the Oncotype DX test in avoiding unnecessary chemotherapy for patients with node-positive breast cancer

2018 Archive

19 December 2018
NICE expands recommendation for the Oncotype DX test to more patients with early-stage breast cancer

11 December, 2018
New long-term evidence from large study reinforces value of the Oncotype DX Breast Recurrence Score test to guide adjuvant chemotherapy treatment, confirming TAILORx conclusions

22 October, 2018
New real-world evidence confirms value of the Oncotype DX test in clinical practice for patients with early-stage breast cancer

3 June, 2018
Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving

2017 Archive

11 December, 2017
New results from large registry with 10-year follow up show excellent outcomes for patients with low Oncotype DX Breast Recurrence Score® results treated with hormonal therapy alone

11 September 2017
Genomic test shows that half of under-40s with early breast cancer have excellent prognosis despite not having chemotherapy treatment

12 July 2017
Updated St. Gallen International Breast Cancer Guidelines reinforce important role of genomic testing in treatment of early breast cancer

13 June 2017
New data show important role of genomic testing in treatment of older breast cancer patients

20 March 2017
Genomic Health’s Oncotype DX breast cancer test can significantly improve patient outcomes for node-positive patients, international studies reveal

6 February 2017
NHS adoption of Oncotype DX test leads to substantial reduction in unnecessary chemotherapy for UK breast cancer patients

2016 Archive

12 December 2016
New data demonstrate that Oncotype DX can help guide treatment decisions before breast cancer surgery enabling more personalised care, including avoidance of full mastectomy

10 October 2016
Large study shows older breast cancer patients have worse outcomes

20 June 2016
Updated NICE quality standard recommends Oncotype DX® in early-stage breast cancer 

6 June 2016
Oncotype DX presentations at 2016 ASCO® annual meeting reinforce Genomic Health’s leadership in optimising breast cancer treatment

31 May 2016
Innovative Oncotype DX test available in centres throughout West of Scotland Cancer Network to guide treatment decisions for early breast cancer patients

11 March 2016
Five-year outcomes results from European ‘PlanB’ study show that breast cancer patients with low Oncotype DX Recurrence Score® results can be spared chemotherapy despite having high-risk disease by traditional measures


UK and Ireland Media Coverage

The Oncotype DX® assay has been featured in many UK national and local newspapers. Below are some stories which may be of interest to you:

Copyright © 2004- Genomic Health, Inc., an Exact Sciences corporation. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, and Breast Recurrence Score are registered trademarks of Genomic Health, Inc., an Exact Sciences corporation.
Making cancer care smarter.™